Ligandal, a genetic medicine company that uses nanotechnology to develop targeted and personalized therapies, has announced the positive results of laboratory studies that demonstrate the effectiveness of its synthetic peptide, SARS-BLOCK, as a combination treatment and vaccine to COVID-19.
The experiments, in conjunction with the Stroud Lab, University of California San Francisco, demonstrate that SARS-BLOCK halts infection of SARS-CoV-2.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze